Johnson & Johnson (JNJ)
NYSE · Healthcare · Drug Manufacturers - General
$252.93−1.21%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $610B
- P/E (trailing)
- 29.3
- Forward P/E
- 20.9
- Dividend yield
- 2.1%
- 52-week range
- $182.94 – $281.07
- 52-week change
- +35.54%
- EPS (trailing)
- $8.63
- Analyst rating
- 1.9 Buy
- Next earnings
- Oct 13, 2026
Fiscal year to Dec 2025
- Revenue
- $94.2B (+6.05%)
- Net income
- $26.8B
- Diluted EPS
- $11.03
- Free cash flow
- $19.7B
From the company’s annual report on SEC EDGAR.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
Headquarters: New Brunswick, United States · 138,200 employees · jnj.com